AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9915433 — intervention group
Group type: COMPARATOR
Intervention: Open prostatectomy
Number of subjects: 365
Study 7771032 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 100
Study 7771032 — intervention group
Group type: COMPARATOR
Intervention: Combined epidural and general anesthesia (EG)
Number of subjects: 100
Study 7771032 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 100
Study 2182732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose trimethoprim treatment
Number of subjects: 613
Study 2182732 — intervention group
Group type: COMPARATOR
Intervention: 7-day trimethoprim treatment
Number of subjects: 613
Study 870566 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza A/England/42/72 (H3N2) virus vaccine
Number of subjects: 47
Study 870566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 31264391 — intervention group
Group type: EXPERIMENTAL
Intervention: temporally distanced meaning making
Number of subjects: 136
Study 31264391 — intervention group
Group type: EXPERIMENTAL
Intervention: spatially distanced meaning making
Number of subjects: 136
Study 31264391 — intervention group
Group type: COMPARATOR
Intervention: self-immersed meaning making
Number of subjects: 136
Study 28610561 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended care (Act and Feel treatment: an eight-week web-based program based on behavioral activation with integrated monitoring of depressive symptomatology and automatized feedback)
Number of subjects: 300
Study 28610561 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard treatment by GPs or MHWs)
Number of subjects: 300
Study 26293121 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapedotomy surgery
Number of subjects: 133
Study 23549826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma (FFP)
Number of subjects: 0
Study 23549826 — intervention group
Group type: COMPARATOR
Intervention: 20% albumin
Number of subjects: 0
Study 21623642 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (n=50)
Number of subjects: 100
Study 21623642 — intervention group
Group type: COMPARATOR
Intervention: No irbesartan (n=50)
Number of subjects: 100
Study 21623642 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (as a variable)
Number of subjects: 100
Study 19637834 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftalan application
Number of subjects: 82
Study 19637834 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic mud application
Number of subjects: 82
Study 19637834 — intervention group
Group type: COMPARATOR
Intervention: No physical factors (Control)
Number of subjects: 82
Study 16698485 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalens IOL
Number of subjects: 112
Study 16698485 — intervention group
Group type: COMPARATOR
Intervention: Standard monofocal IOL
Number of subjects: 112
Study 15526237 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (target dose 32 mg once daily)
Number of subjects: 0
Study 11309632 — intervention group
Group type: EXPERIMENTAL
Intervention: Early insertion of tympanostomy tubes
Number of subjects: 429
Study 11309632 — intervention group
Group type: COMPARATOR
Intervention: Delayed insertion of tympanostomy tubes
Number of subjects: 429
Study 9312651 — intervention group
Group type: EXPERIMENTAL
Intervention: Welders exposed to welding fumes
Number of subjects: 20
Study 9312651 — intervention group
Group type: COMPARATOR
Intervention: Welders who smoke
Number of subjects: 20
Study 7685221 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (activated clotting time, > 180 sec)
Number of subjects: 15
Study 7685221 — intervention group
Group type: COMPARATOR
Intervention: Full-dose heparin (activated clotting time, > 480 sec) with high-dose aprotinin
Number of subjects: 15
Study 3319461 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA suppositories, 500 mg t.i.d. for 6 weeks
Number of subjects: 27
Study 3319461 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 27
Study 29530060 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline and policy implementation strategies
Number of subjects: 121
Study 29530060 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 121
Study 26285003 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (INT): One-time consultation with a sleep specialist
Number of subjects: 137
Study 25057103 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet during pregnancy
Number of subjects: 460
Study 25057103 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 460
Study 22436400 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) with 30 μg of ethinylestradiol (EE)
Number of subjects: 84
Study 22436400 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs) with 15 μg of ethinylestradiol (EE)
Number of subjects: 84
Study 22436400 — intervention group
Group type: COMPARATOR
Intervention: Nonusers of COCs
Number of subjects: 84
Study 22436400 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives (COCs)
Number of subjects: 84
Study 20701812 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit with Practice Nurse
Number of subjects: 0
Study 20701812 — intervention group
Group type: EXPERIMENTAL
Intervention: Quitline referral
Number of subjects: 0
Study 20701812 — intervention group
Group type: COMPARATOR
Intervention: GP usual care
Number of subjects: 0
Study 19641768 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (In-ovation brackets)
Number of subjects: 20
Study 19641768 — intervention group
Group type: COMPARATOR
Intervention: Conventional preadjusted straight wire brackets
Number of subjects: 20
Study 16162943 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day ezetimibe combined with 25 g/day spread containing 2.0 g of plant sterols
Number of subjects: 40
Study 16162943 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g/day spread containing 2.0 g of plant sterols
Number of subjects: 40
Study 16162943 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day ezetimibe
Number of subjects: 40
Study 16162943 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment consisting of 25 g/day control spread
Number of subjects: 40
Study 12578865 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma hs-CRP levels in CAD patients
Number of subjects: 101
Study 12578865 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adiponectin concentrations in CAD patients
Number of subjects: 101
Study 12578865 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP mRNA levels in human adipose tissue
Number of subjects: 101
Study 12578865 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP mRNA level in white adipose tissue of adiponectin deficient mice
Number of subjects: 101
Study 10319771 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% saline infusion (30 ml x kg(‐1) x h(‐1))
Number of subjects: 24
Study 10319771 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution infusion (30 ml x kg(‐1) x h(‐1))
Number of subjects: 24
Study 8907138 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphical display of pain levels on bedside wall charts
Number of subjects: 78
Study 8907138 — intervention group
Group type: COMPARATOR
Intervention: Standard periodic pain assessments without graphical display
Number of subjects: 78
Study 1862584 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam daily for ten days
Number of subjects: 212
Study 1862584 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg piroxicam daily for ten days
Number of subjects: 212
Study 1862584 — intervention group
Group type: COMPARATOR
Intervention: Placebo for ten days
Number of subjects: 212
Study 6134861 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol 0.3%
Number of subjects: 0
Study 6134861 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.25%
Number of subjects: 0
Study 31816446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (130 mg intravenous induction)
Number of subjects: 320
Study 31816446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg subcutaneous maintenance every 8 weeks)
Number of subjects: 320
Study 31816446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg subcutaneous maintenance every 12 weeks)
Number of subjects: 320
Study 31816446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 30797387 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (providers attended three group training sessions to enhance communication skills)
Number of subjects: 418
Study 30797387 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 418
Study 28372596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg administered intravenously over 40 minutes) plus manualised psychological therapy
Number of subjects: 96
Study 28372596 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.8 mg/kg administered intravenously over 40 minutes) plus alcohol education control
Number of subjects: 96
Study 28372596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 ml saline 0.9% IV over 40 minutes) plus manualised psychological therapy
Number of subjects: 96
Study 28372596 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 ml saline 0.9% IV over 40 minutes) plus alcohol education control
Number of subjects: 96
Study 25943205 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal and oropharyngeal swabs
Number of subjects: 0
Study 25943205 — intervention group
Group type: COMPARATOR
Intervention: Nasal swabs alone
Number of subjects: 0
Study 23177356 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal method
Number of subjects: 57
Study 23177356 — intervention group
Group type: COMPARATOR
Intervention: Transverse method
Number of subjects: 57
Study 20970888 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 mg/kg IV midazolam
Number of subjects: 182
Study 20970888 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg/kg IV ketamine
Number of subjects: 182
Study 20970888 — intervention group
Group type: COMPARATOR
Intervention: 4 mg/kg IM ketamine
Number of subjects: 182
Study 20970888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 20084738 — intervention group
Group type: EXPERIMENTAL
Intervention: Avon's SS220 Spray
Number of subjects: 12
Study 20084738 — intervention group
Group type: EXPERIMENTAL
Intervention: Avon's SS220 Lotion
Number of subjects: 12
Study 20084738 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayrepel Lotion
Number of subjects: 12
Study 20084738 — intervention group
Group type: EXPERIMENTAL
Intervention: SC Johnson's Autan Bayrepel Lotion
Number of subjects: 12
Study 20084738 — intervention group
Group type: COMPARATOR
Intervention: N,N‐diethyl‐3‐methyl‐benzamide (deet)
Number of subjects: 12
Study 20084738 — intervention group
Group type: COMPARATOR
Intervention: Null repellent (no repellent at all)
Number of subjects: 12
Study 17132121 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration (compression + oscillation)
Number of subjects: 10
Study 17132121 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression alone
Number of subjects: 10
Study 17132121 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillation alone
Number of subjects: 10
Study 17132121 — intervention group
Group type: COMPARATOR
Intervention: Passive expiration alone
Number of subjects: 10
Study 15367257 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival estimates derived from the CAPRIE trial data
Number of subjects: 50000
Study 15367257 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 50000
Study 15367257 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent events
Number of subjects: 50000
Study 15367257 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease in multiple vascular beds
Number of subjects: 50000
Study 11413428 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA)
Number of subjects: 59
Study 11413428 — intervention group
Group type: COMPARATOR
Intervention: Control (no EACA)
Number of subjects: 59
Study 9135928 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 14
Study 8124045 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with antibiotics
Number of subjects: 75
Study 8124045 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clindamycin with sulfamethoxydiazine and/or pyrimethamine
Number of subjects: 75
Study 8124045 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with clindamycin alone
Number of subjects: 75
Study 8124045 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid therapy
Number of subjects: 75
Study 8124045 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clindamycin and pyrimethamine
Number of subjects: 75
Study 8124045 — intervention group
Group type: COMPARATOR
Intervention: Any therapeutic concept used
Number of subjects: 75
Study 2887327 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 1 mg, intravenous administration)
Number of subjects: 60
Study 2887327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 29970059 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mg of alendronate sodium and 5600 IU of vitamin D3 (ALN/D5600)
Number of subjects: 219
Study 29970059 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol (0.25 μg daily)
Number of subjects: 219
Study 28400148 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical betulin gel (TBG) consisting of 10% birch bark extract and 90% sunflower oil
Number of subjects: 219
Study 28400148 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (a non-adhesive moist wound dressing)
Number of subjects: 219
Study 26270686 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (100 mg/d)
Number of subjects: 241
Study 26270686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 26270686 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive (1,3)-β-d-glucan (ßDG) result
Number of subjects: 241
Study 24041914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.5 ml Optison
Number of subjects: 30
Study 24041914 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 0.5 ml placebo (5% dextrose)
Number of subjects: 30
Study 21420281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention based on selecting participants with high population attributable fraction (AF(p))
Number of subjects: 0
Study 21420281 — intervention group
Group type: COMPARATOR
Intervention: Traditional high risk/high response approach to trial design
Number of subjects: 0
Study 18667790 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution computed tomography (HRCT)
Number of subjects: 30
Study 18667790 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 30
Study 16642229 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed pleura (CP) group, n=120
Number of subjects: 240
Study 16642229 — intervention group
Group type: COMPARATOR
Intervention: Opened pleura (OP) group, n=120
Number of subjects: 240
Study 12707240 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based cardiac rehabilitation (Hosp-CR)
Number of subjects: 270
Study 12707240 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation (Home-CR)
Number of subjects: 270
Study 12707240 — intervention group
Group type: COMPARATOR
Intervention: No cardiac rehabilitation (Control)
Number of subjects: 270
Study 11899644 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with hematopoietic stem-cell transplantation (HDC/HSCT)
Number of subjects: 0
Study 8659770 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.1%
Number of subjects: 66
Study 8659770 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.1% with bupivacaine 0.1%
Number of subjects: 66
Study 8659770 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 0.1% with bupivacaine 0.01%
Number of subjects: 66
Study 1388643 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) at 150 mg daily
Number of subjects: 5
Study 1388643 — intervention group
Group type: COMPARATOR
Intervention: Cocaine doses (0.125 to 0.5 mg/kg)
Number of subjects: 5
Study 2932833 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasonic bubble detection
Number of subjects: 83
Study 31099330 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 240 mg (single intramuscular injection)
Number of subjects: 720
Study 31099330 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 500 mg (single intramuscular injection)
Number of subjects: 720
Study 28410283 — intervention group
Group type: EXPERIMENTAL
Intervention: Acriva Reviol MFM 613 IOL
Number of subjects: 30
Study 28410283 — intervention group
Group type: COMPARATOR
Intervention: AcrySof ReSTOR SN6AD1 IOL
Number of subjects: 30
Study 26827702 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant erythropoietin (10 patients)
Number of subjects: 20
Study 26827702 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 20
Study 24090124 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon infusion set
Number of subjects: 20
Study 24090124 — intervention group
Group type: EXPERIMENTAL
Intervention: Steel infusion set
Number of subjects: 20
Study 24090124 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both types)
Number of subjects: 20
Study 22527351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine 1,000 mg QD with midazolam
Number of subjects: 0
Study 22527351 — intervention group
Group type: EXPERIMENTAL
Intervention: Lersivirine 1,000 mg QD with oral contraceptives (ethinylestradiol and levonorgestrel)
Number of subjects: 0
Study 20113698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame oil (oral administration)
Number of subjects: 64
Study 17684125 — intervention group
Group type: EXPERIMENTAL
Intervention: 201L allele of S201L (TT versus CC)
Number of subjects: 725
Study 17684125 — intervention group
Group type: EXPERIMENTAL
Intervention: 201L allele of S201L (TC versus CC)
Number of subjects: 725
Study 17684125 — intervention group
Group type: EXPERIMENTAL
Intervention: 277E allele of K277E (GG versus AA)
Number of subjects: 725
Study 17684125 — intervention group
Group type: EXPERIMENTAL
Intervention: 277E allele of K277E (GA versus AA)
Number of subjects: 725
Study 17684125 — intervention group
Group type: EXPERIMENTAL
Intervention: TGTGCG haplotype of six informative single nucleotide polymorphisms
Number of subjects: 725
Study 17684125 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular ibuprofen users homozygous for the variant allele at either M9V or D175G
Number of subjects: 725
Study 16275814 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride (low, medium, and high doses ranging from 7.5 mg/d to 50.0 mg/d)
Number of subjects: 72
Study 16275814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 11902618 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate disconfirmers
Number of subjects: 0
Study 11902618 — intervention group
Group type: COMPARATOR
Intervention: Extreme disconfirmers
Number of subjects: 0
Study 11902618 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate disconfirmers encountered before stereotype is well-established
Number of subjects: 0
Study 10202979 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberrant expression of nitric oxide synthase III (NOS III) gene and neuritic sprouting in neurodegenerative diseases
Number of subjects: 0
Study 10202979 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS III expression and neuritic sprouting
Number of subjects: 0
Study 10202979 — intervention group
Group type: EXPERIMENTAL
Intervention: Double label immunohistochemical staining studies
Number of subjects: 0
Study 7873952 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving treatment
Number of subjects: 91
Study 7873952 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 91
Study 7873952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 2144205 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex and flutamide
Number of subjects: 0
Study 2144205 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 0
Study 797086 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid (EACA)
Number of subjects: 40
Study 797086 — intervention group
Group type: COMPARATOR
Intervention: Control group (transurethral surgery)
Number of subjects: 40
Study 31621523 — intervention group
Group type: EXPERIMENTAL
Intervention: EpxDiabetes intervention group
Number of subjects: 65
Study 31621523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 65
Study 30905242 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% NaF mouth rinse used at bedtime in combination with 0.22% NaF dentifrice 2 times/day
Number of subjects: 12
Study 30905242 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% NaF brush-on gel used at bedtime in combination with 0.22% NaF dentifrice 2 times/day
Number of subjects: 12
Study 30905242 — intervention group
Group type: COMPARATOR
Intervention: 0.22% NaF dentifrice used 2 times/day
Number of subjects: 12
Study 28092973 — intervention group
Group type: EXPERIMENTAL
Intervention: PHCTR1 polymorphism
Number of subjects: 1345
Study 28092973 — intervention group
Group type: EXPERIMENTAL
Intervention: WDR12 polymorphism
Number of subjects: 1345
Study 28092973 — intervention group
Group type: EXPERIMENTAL
Intervention: GRS 18
Number of subjects: 1345
Study 28092973 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAMTS7 and LPA polymorphisms
Number of subjects: 1345
Study 26219154 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 0
Study 26219154 — intervention group
Group type: COMPARATOR
Intervention: Conventional metal uterine curettage
Number of subjects: 0
Study 23942177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐fat vegan diet and weekly group meetings (Intervention)
Number of subjects: 292
Study 23942177 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (Control)
Number of subjects: 292
Study 21872918 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents
Number of subjects: 610